Page last updated: 2024-09-05

sb 203580 and perfosfamide

sb 203580 has been researched along with perfosfamide in 1 studies

Compound Research Comparison

Studies
(sb 203580)
Trials
(sb 203580)
Recent Studies (post-2010)
(sb 203580)
Studies
(perfosfamide)
Trials
(perfosfamide)
Recent Studies (post-2010) (perfosfamide)
3,48941,1373281815

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Chen, KL; Li, XF; Luo, J; Niu, HQ; Qin, KL; Zhao, WP; Zhao, XC1

Other Studies

1 other study(ies) available for sb 203580 and perfosfamide

ArticleYear
Combination of 4-hydroperoxy cyclophosphamide and methotrexate inhibits IL-6/sIL-6R-induced RANKL expression in fibroblast-like synoviocytes via suppression of the JAK2/STAT3 and p38MAPK signaling pathway.
    International immunopharmacology, 2018, Volume: 61

    Topics: Arthritis, Rheumatoid; Cells, Cultured; Cyclophosphamide; Drug Therapy, Combination; Fibroblasts; Gene Expression Regulation; Humans; Imidazoles; Interleukin-6; Janus Kinase 2; Methotrexate; p38 Mitogen-Activated Protein Kinases; Pyridines; RANK Ligand; Receptors, Interleukin-6; Signal Transduction; STAT3 Transcription Factor; Synoviocytes; Tyrphostins

2018